Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | SO-C101 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SO-C101 | RL-I15|RLI 15|RLI-15|RLI15|SO C101|SOC101|SOT 101|SOT-101|SOT101 | SO-C101 is a fusion protein comprising IL15 and IL15RA, which increases the number of natural killer (NK) cells and memory CD8+ T-cells to launch an immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04234113 | Phase I | SO-C101 Pembrolizumab + SO-C101 | Study of SO-C101 and SO-C101in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | 1 |